Program
brexpiprazole
Also written as “Brexpiprazole”, “OPC-34712” and “Brexpiprazole (OPC-34712)”.
Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Stress Disorders, Post-Traumatic · Alzheimer Disease · Mania, led by 3 companies.
Drug pageBrexpiprazole: every studyAll 79 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Otsukaits history only | 600 open or running | phase 4since Mar 29, 2021 | Nov 24, 2008 | none ahead |
| H. Lundbeck | 90 open or running | phase 3since Mar 11, 2013 | Mar 11, 2013 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Dec 4, 2025 | Dec 4, 2025 | none ahead |
Also a collaborator on its studies: Quintiles.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of H. Lundbeck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 11, 2013First studies: 2 phase 3 studies in SchizophreniaFirst studyNCT01810380, NCT01810783
- Apr 4, 20132 phase 3 studies in Depressive Disorder, MajorNCT01837797, NCT01838681
- Sep 11, 20133 phase 3 studiesNCT01942785, NCT01942733, NCT01944969
- Nov 13, 2013Phase 3 study in Stress Disorders, Post-TraumaticNCT01987960 · 417 enrolled · United States, Estonia, Finland and more
- Apr 29, 2016Phase 3 study in SchizophreniaNCT02758067
TargetBeta
“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
Studies
All 9 H. Lundbeck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02758067Schizophrenia | 3 | Withdrawn | Jun 2016 | 0 |
| NCT01987960Stress Disorders, Post-Traumatic · United States, Estonia, Finland and more | 3 | Terminated | Oct 2015 | 417 |
| NCT01944969Depressive Disorder, Major · United States | 3 | Terminated | May 2014 | 26 |
| NCT01942785Depressive Disorder, Major · United States | 3 | Completed | Jul 2014 | 55 |
| NCT01942733Parasomnias | 3 | Completed | Aug 2014 | 44 |
| NCT01838681Depressive Disorder, Major · United States, Bulgaria, Canada and more | 3 | Completed | Jun 2016 | 1,986 |
| NCT01837797Depressive Disorder, Major · United States | 3 | Terminated | May 2014 | 129 |
| NCT01810783Schizophrenia · United States, Estonia, Poland and more | 3 | Completed | Dec 2015 | 210 |
| NCT01810380Schizophrenia · United States | 3 | Completed | Dec 2014 | 468 |
How it is read
Names in the registry
- “Brexpiprazole”, 44 entries
- “OPC-34712”, 17 entries
- “Brexpiprazole (OPC-34712)”, 2 entries
- “Brexpiprazole, OPC-34712”, 2 entries
- “OPC-34712 + ADT”, 2 entries
Codes read as this program: OPDC34712.
Conditions, from the studies’ own filings
- Schizophrenia, 26 studies
- Depressive Disorder, Major, 21 studies
- Stress Disorders, Post-Traumatic, 4 studies
- Alzheimer Disease, 4 studies
- Mania, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.